Hans Gelderblom
Hans Gelderblom
LUMC
Verified email at lumc.nl
Title
Cited by
Cited by
Year
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ...
The Lancet 381 (9863), 303-312, 2013
19442013
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom, J Verweij, K Nooter, A Sparreboom
European journal of cancer 37 (13), 1590-1598, 2001
15682001
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
WTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ...
The Lancet 379 (9829), 1879-1886, 2012
13432012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...
The Lancet 381 (9863), 295-302, 2013
9822013
Combination chemotherapy in advanced adrenocortical carcinoma
M Fassnacht, M Terzolo, B Allolio, E Baudin, H Haak, A Berruti, S Welin, ...
New England Journal of Medicine 366 (23), 2189-2197, 2012
5512012
The clinical approach towards chondrosarcoma
H Gelderblom, PCW Hogendoorn, SD Dijkstra, CS Van Rijswijk, AD Krol, ...
The oncologist 13 (3), 320-329, 2008
5272008
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
5132014
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, JY Blay, A Bertuzzi, S Bielack, B Bjerkehagen, S Bonvalot, ...
439*2014
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up
PG Casali, L Jost, P Reichardt, M Schlemmer, JY Blay, ...
Annals of Oncology 20 (suppl_4), iv64-iv67, 2009
438*2009
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ...
The Lancet 387 (10028), 1629-1637, 2016
4212016
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications
A Sparreboom, L van Zuylen, E Brouwer, WJ Loos, P de Bruijn, ...
Cancer research 59 (7), 1454-1457, 1999
3941999
Clinical pharmacokinetics of tyrosine kinase inhibitors
NP van Erp, H Gelderblom, HJ Guchelaar
Cancer treatment reviews 35 (8), 692-706, 2009
3652009
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ...
European journal of cancer 47 (16), 2431-2445, 2011
3432011
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Berruti, E Baudin, H Gelderblom, HR Haak, F Porpiglia, M Fassnacht, ...
Annals of oncology 23 (suppl_7), vii131-vii138, 2012
3142012
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials
P Rutkowski, M Van Glabbeke, CJ Rankin, W Ruka, BP Rubin, ...
Journal of clinical oncology 28 (10), 1772, 2010
3102010
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ESMO/European Sarcoma Network Working Group
Annals of oncology: official journal of the European Society for Medical …, 2014
2952014
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
A Sparreboom, H Gelderblom, S Marsh, R Ahluwalia, R Obach, P Principe, ...
Clinical Pharmacology & Therapeutics 76 (1), 38-44, 2004
2772004
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ...
Annals of Oncology 29 (Supplement_4), iv51-iv67, 2018
2592018
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
H Hoftijzer, KA Heemstra, H Morreau, MP Stokkel, EP Corssmit, ...
European journal of endocrinology 161 (6), 923-931, 2009
2582009
Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
ESMO/European Sarcoma Network Working Group
Annals of oncology: official journal of the European Society for Medical …, 2012
2532012
The system can't perform the operation now. Try again later.
Articles 1–20